- Conditions
- Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Olanzapine, Chemotherapy (cisplatin or cyclophosphamide and doxorubicin), Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant), Placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 401 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 177
- States / cities
- Anchorage, Alaska • Burbank, California • Dublin, California + 109 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 34
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- Palonosetron, Ondansetron, Placebo to Ondansetron, Placebo to Palonosetron
- Drug
- Lead sponsor
- Helsinn Healthcare SA
- Industry
- Eligibility
- Up to 16 Years
- Enrollment
- 502 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • Duarte, California • Aurora, Colorado + 11 more
- Conditions
- Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- dexamethasone, gabapentin, placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 430 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 247
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 163 more
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced, Chemotherapy-Induced Nausea and Vomiting
- Interventions
- GW679769, Dexamethasone, Ondansetron Hydrochloride
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 722 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Corona, California • Greenbrae, California + 43 more
- Conditions
- Acute Myelogenous Leukemia, Chemotherapy-induced Nausea and Vomiting
- Interventions
- Ondansetron, Palonosetron
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Malignant Neoplasm
- Interventions
- Palonosetron Hydrochloride, Ondansetron Hydrochloride, Dexamethasone, Fosaprepitant Dimeglumine, Olanzapine, Placebo
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 690 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 565
- States / cities
- Birmingham, Alabama • Fairbanks, Alaska • Kingman, Arizona + 372 more
- Conditions
- Chemotherapy-induced Nausea and Vomiting (CINV)
- Interventions
- Netupitant, Palonosetron
- Drug
- Lead sponsor
- Helsinn Healthcare SA
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 5
- States / cities
- Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida + 2 more
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- Intranasal granisetron
- Drug
- Lead sponsor
- Shin Nippon Biomedical Laboratories, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- The Study Is Managed by Kendle International, in Wilmington, North Carolina
- Conditions
- Malignant Neoplasm
- Interventions
- Netupitant, Palonosetron Hydrochloride, Questionnaire Administration
- Drug · Other
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC
- Interventions
- palonesetron
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 9
- States / cities
- Sunrise, Florida • Galesburg, Illinois • Skokie, Illinois + 6 more
- Conditions
- Nausea With Vomiting Chemotherapy-Induced
- Interventions
- Palonosetron Hydrochloride Buccal Film 0.25 Mg, Palonosetron Hydrochloride Buccal Film 0.5 Mg, Palonosetron Hydrochloride, 0.25 Mg/5 mL Intravenous Solution
- Drug
- Lead sponsor
- Xiamen LP Pharmaceutical Co., Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 7
- States / cities
- Anaheim, California • Ocala, Florida • Skokie, Illinois + 4 more
- Conditions
- Chemotherapy Induced Nausea and Vomiting
- Interventions
- Akynzeo
- Drug
- Lead sponsor
- Simon Williamson Clinic
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Mount Olive, Alabama
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- APF530, Ondansetron, Ondansetron placebo, APF530 placebo, Fosaprepitant, Dexamethasone
- Drug
- Lead sponsor
- Heron Therapeutics
- Industry
- Eligibility
- 18 Years to 87 Years
- Enrollment
- 942 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Downey, California • Riverside, California + 4 more
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- fosnetupitant/ palonosetron, netupitant/palonosetron, dexamethasone
- Drug
- Lead sponsor
- Helsinn Healthcare SA
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 36
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Anaheim, California + 32 more
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Fosaprepitant Dimeglumine, 5-HT3 antagonist, Dexamethasone
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 2 more
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- GRANISETRON EXTENDED RELEASE INJECTION (GERSC)
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Rolapitant, Granisetron, Dexamethasone, Placebo
- Drug
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,369 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx
- Interventions
- fosaprepitant dimeglumine, cisplatin, palonosetron hydrochloride, dexamethasone, Functional Living Index-Emesis Questionnaire, Emesis Diary, Radiotherapy
- Drug · Other · Behavioral + 1 more
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Rolapitant, Granisetron, dexamethasone, Placebo
- Drug
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 532 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Chemotherapy-Induced Nausea and Vomiting (CINV)
- Interventions
- SUSTOL
- Drug
- Lead sponsor
- Heron Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 2
- States / cities
- Hattiesburg, Mississippi • Canton, Ohio
- Conditions
- Sarcoma, Chemotherapy-induced Nausea and Vomiting, Effects of Chemotherapy, Adverse Effects of Medical Drugs
- Interventions
- Fosaprepitant, Dexamethasone, 5HT3 receptor antagonist, Ifosfamide-based chemotherapy (AI), Doxorubicin, Mesna, Ifosfamide, Vincristine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chemotherapy Induced Nausea and Vomiting
- Interventions
- dronabinol, ondansetron, dronabinol/ondansetron, placebo
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 43
- States / cities
- Tucson, Arizona • Anaheim, California • Fountain Valley, California + 37 more
- Conditions
- Chemotherapy Induced Nausea and Vomiting
- Interventions
- granisetron transdermal system, Granisetron IV
- Drug
- Lead sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
- Industry
- Eligibility
- 13 Years to 17 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Orange, California • Aurora, Colorado + 8 more
- Conditions
- Complications of Bone Marrow Transplant, Hematologic Neoplasms
- Interventions
- Olanzapine, Placebo
- Drug
- Lead sponsor
- Augusta University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Augusta, Georgia